Mizuho Reiterates Neutral Rating for Teva (TEVA) Following CEO Departure
Tweet Send to a Friend
Mizuho Securities analyst Irina Koffler maintains Neutral rating and $40 price target on Teva Pharmaceuticals (NYSE: TEVA) suggesting management change ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
